Ab­b­Vie preps a chal­lenge to a ri­val mi­graine drug from Bio­haven, spelling out an up­beat set of PhI­II da­ta

Phase III ad­vance tri­al da­ta for Ab­b­Vie’s mi­graine pre­ven­tion drug ato­gepant look good — but are the re­sults good enough to ri­val Bio­haven’s two-in-one treat­ment and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER